C
Caitlin E. Mills
Researcher at Harvard University
Publications - 35
Citations - 1198
Caitlin E. Mills is an academic researcher from Harvard University. The author has contributed to research in topics: Cell cycle & Palbociclib. The author has an hindex of 11, co-authored 30 publications receiving 647 citations. Previous affiliations of Caitlin E. Mills include Mount Allison University & McMaster University.
Papers
More filters
Journal ArticleDOI
The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations
Alexandra B Keenan,Sherry L. Jenkins,Kathleen M. Jagodnik,Simon Koplev,Edward He,Denis Torre,Zichen Wang,Anders B. Dohlman,Moshe C. Silverstein,Alexander Lachmann,Maxim V. Kuleshov,Avi Ma'ayan,Vasileios Stathias,Raymond Terryn,Daniel J. Cooper,Michele Forlin,Amar Koleti,Dusica Vidovic,Caty Chung,Stephan C. Schürer,Jouzas Vasiliauskas,Marcin Pilarczyk,Behrouz Shamsaei,Mehdi Fazel,Yan Ren,Wen Niu,Nicholas A. Clark,Shana White,Naim Al Mahi,Lixia Zhang,Michal Kouril,John F. Reichard,Siva Sivaganesan,Mario Medvedovic,Jaroslaw Meller,Rick J. Koch,Marc R. Birtwistle,Ravi Iyengar,Eric A. Sobie,Evren U. Azeloglu,Julia A. Kaye,Jeannette Osterloh,Kelly Haston,Jaslin Kalra,Steve Finkbiener,Jonathan Z. Li,Pamela Milani,Miriam Adam,Renan Escalante-Chong,Karen Sachs,Alexander LeNail,Divya Ramamoorthy,Ernest Fraenkel,Gavin Daigle,Uzma Hussain,Alyssa Coye,Jeffrey D. Rothstein,Dhruv Sareen,Loren Ornelas,Maria G. Banuelos,Berhan Mandefro,Ritchie Ho,Clive N. Svendsen,Ryan G. Lim,Jennifer Stocksdale,Malcolm Casale,Terri G. Thompson,Jie Wu,Leslie M. Thompson,Victoria Dardov,Vidya Venkatraman,Andrea Matlock,Jennifer E. Van Eyk,Jacob D. Jaffe,Malvina Papanastasiou,Aravind Subramanian,Todd R. Golub,Sean D. Erickson,Mohammad Fallahi-Sichani,Marc Hafner,Nathanael S. Gray,Jia-Ren Lin,Caitlin E. Mills,Jeremy L. Muhlich,Mario Niepel,Caroline E. Shamu,Elizabeth H. Williams,David Wrobel,Peter K. Sorger,Laura M. Heiser,Joe W. Gray,James E. Korkola,Gordon B. Mills,Mark A. LaBarge,Mark A. LaBarge,Heidi S. Feiler,Mark A. Dane,Elmar Bucher,Michel Nederlof,Damir Sudar,Sean M. Gross,David Kilburn,Rebecca Smith,Kaylyn Devlin,Ron Margolis,Leslie Derr,Albert Lee,Ajay Pillai +107 more
TL;DR: The LINCS program focuses on cellular physiology shared among tissues and cell types relevant to an array of diseases, including cancer, heart disease, and neurodegenerative disorders.
Journal ArticleDOI
A single-cell landscape of high-grade serous ovarian cancer.
Benjamin Izar,Itay Tirosh,Elizabeth H. Stover,Isaac Wakiro,Michael S. Cuoco,Idan Alter,Christopher Rodman,Rachel Leeson,Mei-Ju Su,Parin Shah,Marcin P. Iwanicki,Sarah R. Walker,Abhay Kanodia,Johannes C. Melms,Shaolin Mei,Jia-Ren Lin,Caroline B. M. Porter,Michal Slyper,Julia Waldman,Livnat Jerby-Arnon,Orr Ashenberg,Titus J. Brinker,Caitlin E. Mills,Meri Rogava,Sébastien Vigneau,Peter K. Sorger,Levi A. Garraway,Panagiotis A. Konstantinopoulos,Joyce F. Liu,Ursula A. Matulonis,Bruce E. Johnson,Orit Rozenblatt-Rosen,Asaf Rotem,Asaf Rotem,Aviv Regev +34 more
TL;DR: Significant inter-patient variability is found in the composition and functional programs of ascites cells, including immunomodulatory fibroblast sub-populations and dichotomous macrophage populations, which contributes to resolving the HSGOC landscape and provides a resource for the development of novel therapeutic approaches.
Journal ArticleDOI
Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity.
Marc Hafner,Caitlin E. Mills,Kartik Subramanian,Chen Chen,Mirra Chung,Sarah A. Boswell,Robert A. Everley,Changchang Liu,Charlotte S. Walmsley,Dejan Juric,Peter K. Sorger +10 more
TL;DR: Five different phenotypic and biochemical assays are used to compare approved inhibitors of cyclin-dependent kinases 4/6-collectively regarded as breakthroughs in the treatment of hormone receptor-positive breast cancer to uncover underappreciated differences in CDK4/6 inhibitor activities with potential importance in treating human patients.
Journal ArticleDOI
A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines.
Mario Niepel,Marc Hafner,Caitlin E. Mills,Kartik Subramanian,Elizabeth H. Williams,Mirra Chung,Benjamin L. Gaudio,Anne Marie Barrette,Alan D Stern,Bin Hu,James E. Korkola,Joe W. Gray,Marc R. Birtwistle,Laura M. Heiser,Peter K. Sorger +14 more
TL;DR: The reproducibility of a prototypical perturbational assay: quantifying the responsiveness of cultured cells to anti-cancer drugs and ways to identify context-sensitive factors, thereby improving both the theory and practice of reproducible cell-based assays are provided.
Journal ArticleDOI
Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype.
Calla M. Olson,Yanke Liang,Alan L. Leggett,Woojun D Park,Lianbo Li,Caitlin E. Mills,Selma Z. Elsarrag,Scott B. Ficarro,Tinghu Zhang,Robert Düster,Matthias Geyer,Taebo Sim,Jarrod A. Marto,Peter K. Sorger,Kenneth D. Westover,Charles Y. Lin,Nicholas Kwiatkowski,Nathanael S. Gray +17 more
TL;DR: Treatment with YKL-5-124 resulted in no change to RNA polymerase II C-terminal domain phosphorylation, and selective inhibition of CDK7 may be useful for treatment of cancers marked by E2F misregulation.